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Abstract: Postherpetic neuralgia (PHN) is a devastating, chronic pain syndrome that can 
develop following an outbreak of herpes zoster and becomes increasingly common as patients 
age. PHN can be difﬁ  cult to treat and often requires trials of multiple agents to achieve signiﬁ  cant 
pain relief. Pregabalin is the newest agent to gain approval for PHN. Data suggest efﬁ  cacy for 
relief of pain and sleep disturbance secondary to PHN in affected patients. Although there are 
no head-to-head comparisons, pregabalin appears comparable to gabapentin and other ﬁ  rst-line 
agents for treating PHN.
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Introduction
Herpes zoster (HZ) or shingles is a result of reactivation of the varicella zoster virus 
(VZV), the same virus that causes chickenpox. After the acute varicella infection 
(ie, chickenpox in childhood), the virus can lie dormant for decades in sensory nerve 
ganglia, usually involving the lumbar, thoracic and trigeminal ganglia. HZ results 
when dormant VZV in these nerves is reactivated, possibly secondary to a decline in 
speciﬁ  c cell-mediated immunity to VZV with aging and/or immunosuppression. The 
majority of cases of HZ are seen in older adults, with incidence increasing sharply at 
around 50 years of age and doubling by age 80.1,2 Neither gender, race, nor ethnicity 
appear to be risk factors for HZ.3
A patient with HZ may ﬁ  rst develop a prodromal syndrome with fever, malaise, 
and pain that is generally localized to the affected dermatome. This pain may include 
burning, itching, and hypersensitivity and may precede the rash by 4 to 5 days.1,4 
Because many patients initially present with severe pain as their chief complaint, 
patients are often misdiagnosed.
Pain is the major symptom of HZ, and, in most patients, the pain resolves spontane-
ously over time. However, about 10% to 15% of patients develop chronic, debilitating 
postherpetic pain that persists after the characteristic rash disappears2,5 with some 
patients experiencing persistent pain for years.6 Posterherpetic neuralgia (PHN) is 
deﬁ  ned in the literature as pain that persists for more than 1 to 6 months after rash 
resolution. In most clinical trials, PHN is deﬁ  ned as pain persisting for more than 
3 months after resolution of the rash.2,3,5
PHN is often characterized by a combination of throbbing or burning pain, inter-
mittent sharp pains, altered sensory perception, including paresthesia, and allodynia 
(painful response to an innocuous stimulus).3 The pain may extend beyond the borders 
of the original zoster rash. The variety of symptoms likely result from injury to the 
dorsal root ganglia and dorsal horn as well as injury to the peripheral nerves. The 
incidence, duration, and severity are all related to increasing age; in fact, PHN is 
uncommon in those less than 60 years of age.1–4 Presence of pain prior to rash eruption, Clinical Interventions in Aging 2009:4 18
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rash severity, and inﬂ  ammation and fever are thought to all 
have an effect on PHN severity.3 PHN pain is often severe, 
unrelenting, and exhausting. As a result, PHN can dramati-
cally affect a patient’s quality of life and functional status. 
Patients may develop insomnia, weight loss, chronic fatigue, 
and an inability to perform daily activities. It is estimated that 
more than 50% of patients with PHN have sleep disturbances, 
and about 25% report a decrease in socialization. Eventually 
a patient with PHN may lose the ability for self-care, leading 
to depression and social isolation.1,2,7,8
Successful management of PHN can be complicated 
and challenging, especially with the fact that there is no 
deﬁ  nitive treatment algorithm speciﬁ  cally for patients with 
PHN. In recent years, there have been a number of published 
guidelines proposed for the treatment of neuropathic pain in 
general.5,9–12 These recommendations are essentially based on 
evidence of efﬁ  cacy from randomized controlled trials (RCTs) 
of pharmacologic therapies; there is a lack of clinical trials 
directly comparing efﬁ  cacy and safety of one pharmacotherapy 
versus another.12,13 These guidelines uniformly recommend 
tricyclic antidepressants (TCAs), opioids, and anticonvulsants 
as ﬁ  rst-line therapeutic options for treating neuropathic pain. 
First or second-line recommendations include topical treat-
ments (eg, topical lidocaine), depending on the source.
Both gabapentin and pregabalin (PGB) are oral 
anticonvulsants approved for the management of PHN. They 
are both recommended as ﬁ  rst-line therapeutic choices for 
neuropathic pain based on several RCTs.5,9–12 Although there 
have been no head-to-head RCTs between these 2 agents 
in patients with PHN, both have signiﬁ  cantly reduced pain 
(p   0.01) and improved sleep (p   0.01).7,15–18
This review will focus speciﬁ  cally on PGB, the newest 
agent to gain approval for PHN. A general overview of the drug 
will be given, followed by a review of clinical trial efﬁ  cacy 
and adverse effects data in PHN patients, concluding with a 
discussion of PGB’s place in therapy in treating PHN.
Pregabalin overview: pharmacology 
and pharmacokinetics
PGB was ﬁ  rst approved in the European Union by the European 
Agency for the Evaluation of Medicinal Products for the treat-
ment of peripheral neuropathic pain in July 2004. PGB received 
conditional approval by the US Food and Drug Administration 
for the treatment of diabetic peripheral neuropathy (DPN) and 
PHN in December 2004 and was granted ﬁ  nal approval after 
controlled substance scheduling by the US Drug Enforcement 
Agency in August 2005.19 PGB is a schedule V controlled sub-
stance based on a study with 15 recreational sedative/hypnotic 
drug users who rated the “desirability” of a single dose of PGB 
450 mg as similar to a single dose of diazepam 30 mg.19–21 
Indeed, euphoria was reported in 4% of PGB-treated patients 
versus 1% of placebo-treated patients in over 5500 patients in 
controlled clinical trials, and withdrawal symptoms suggestive 
of physical dependence were reported upon abrupt discontinu-
ation of PGB in some studies.20
The exact mechanism of action of PGB is unclear but 
is thought to be similar to that of gabapentin. PGB is a 
structural analogue of GABA, but it is inactive at GABA-A 
or -B receptors, it is not converted into GABA or a GABA 
antagonist, and it does not affect GABA uptake.7,21,22 PGB is 
an alpha2-delta ligand. PGB may alter the release of several 
neurotransmitters, by selectively binding to the alpha2-delta 
auxiliary protein subunit of voltage-gated calcium channels. 
By tightly binding to alpha2-delta protein, PGB reduces the 
inﬂ  ux of calcium, thereby reducing the release of neurotrans-
mitters, including glutamate, norepinephrine, and substance P. 
These mechanisms are thought to result in the anticonvulsant, 
anxiolytic, and analgesic properties exhibited by PGB.
PGB was created in an attempt to develop a compound 
that would retain the biologic activity of gabapentin while 
improving its pharmacokinetic proﬁ  le. PGB is well absorbed 
following oral administration with an oral bioavailabil-
ity of  90%. The bioavailability of gabapentin actually 
decreases from 60% to 27% with increasing doses due to 
saturable absorption (900 mg/day versus 4800 mg/day, 
respectively).20,21,23 Unlike gabapentin, PGB exhibits linear 
pharmacokinetics. Elimination of PGB is virtually propor-
tional to creatinine clearance (CrCl). Dosage adjustments for 
renal dysfunction are provided (Table 1). Ninety-eight percent 
of a dose of PGB is excreted unchanged in the urine, and the 
drug undergoes negligible metabolism with no anticipated 
CYP 450 enzyme drug interactions. PGB pharmacokinetics 
do not appear to be affected by race or gender and have not 
been studied in pediatric patients.20,21,24 Renal clearance of 
PGB appears to decrease with age, consistent with age-related 
changes in renal function. Hence, older adults often require 
renal adjustment of PGB dosing.20 PGB is effectively cleared 
by hemodialysis; 50%–60% is removed from the circula-
tion following a 4-hour hemodialysis session. Therefore, a 
supplemental dose should be given immediately following 
every 4-hour hemodialysis treatment (Table 1).20,21,24
Literature review: pregabalin 
for PHN
The efﬁ  cacy of PGB for management of PHN has been dem-
onstrated in 3 double-blind, placebo-controlled, multicenter Clinical Interventions in Aging 2009:4 19
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clinical trials involving patients with PHN, and 1 randomized, 
double-blind, placebo-controlled study in patients with 
chronic neuropathic pain including PHN.7,14,18,25 Studies 
comparing PGB with other agents used to treat PHN are not 
available. Patients failing to respond to gabapentin were 
excluded from most of these studies.7,14,18 An important point 
to note: all 4 trials described herein were sponsored by the 
manufacturer of PGB (Pﬁ  zer), and the trials were conducted 
at least in part by Pﬁ  zer employees.
An 8-week trial was conducted in 173 patients with PHN, 
deﬁ  ned as pain persisting for  3 months following the healing 
of a HZ rash.14 Concomitant medications that were allowed at 
stable doses during the trial included opioid and non-opioid 
analgesics, NSAIDs, aspirin, acetaminophen ( 4 g/day), and 
antidepressants including SSRIs. Benzodiazepines, skeletal 
muscle relaxants, oral steroids, local and topical agents for PHN, 
and anticonvulsants were prohibited. Patients were randomized 
to either PGB (n = 89) or placebo (n = 84). Doses were given 
three times a day. Those on PGB received either 600 mg/day 
(CrCl   60 mL/min) or 300 mg/day (CrCl 30–60 mL/min). 
This renal dosage adjustment is based on pharmacokinetic 
studies that demonstrated comparable steady-state concentra-
tions of PGB, thus allowing these 2 subsets to be combined 
as a single PGB treatment arm for the purpose of pain relief 
assessment.14,15 Mean age of the patients was 71.5 years, with 
82% of patients over 65 years of age, and the mean duration 
of PHN was 33.8 months. Patients were required to have an 
average daily pain score of at least 4 on an 11-point numerical 
rating scale (0 = no pain; 10 = worst possible pain) during the 
7-day baseline period. Additionally, patients were required to 
have a pain score of  40 mm on the 100 mm visual analog 
scale (VAS) of the Short-Form McGill Pain Questionnaire 
(SF-MPQ) at baseline and at randomization. The primary 
efﬁ  cacy point was the mean of the last 7 daily pain scores on 
the 11-point pain scale. Patients treated with PGB had greater 
reductions in mean pain scores than those treated with placebo 
(3.60 versus 5.29; p   0.0001). A decrease in pain was seen 
in PGB-treated patients as early as day 1 and maintained 
throughout the study. In addition, signiﬁ  cantly more patients 
receiving PGB had  50% reduction in mean pain scores than 
those receiving placebo. As a secondary endpoint, daily sleep 
interference scores were measured for all study participants by 
assessing the degree to which pain interfered with sleep during 
the previous 24 hours on an 11-point numerical rating scale. 
A score of 0 indicates pain did not interfere with sleep, and a 
score of 10 indicates pain completely interfered with sleep. 
Sleep interference scores were recorded in subjects’ daily 
diaries upon awakening. Signiﬁ  cant improvements in mean 
sleep interference scores (derived from subjects’ last 7 days 
of diary entries while receiving study drug) were observed. 
At study end, the mean sleep interference score was 1.93 in 
PGB-treated patients versus 3.51 in placebo-treated subjects 
(p = 0.0001).14
A second 8-week trial was conducted in 238 patients 
with PHN of  6 months in duration after the healing of 
the HZ rash.7 Concomitant medications that were allowed 
at stable doses during the study period included NSAIDs, 
acetaminophen, opioid and non-opioid analgesics, and 
antidepressants. Anticonvulsants and benzodiazepines had 
to be discontinued at least 14 days prior to receiving study 
medication. Patients with a CrCl   30 mL/min were excluded 
from the trial. Patients were randomized to either PGB 
150 mg/day (n = 81), PGB 300 mg/day (n = 76), or placebo 
(n = 81). Doses were given three times a day. Mean age of 
the patients was similar to those in the study by Dworkin and 
colleagues (73.2 years, 71.3, and 71.9 years for the placebo, 
150 mg/day, and 300 mg/day groups, respectively), and the 
mean duration of PHN ranged from 44.8 to 40.7 months for 
the placebo, 150 mg/day, and 300 mg/day groups respec-
tively. Patients were required to have an average daily pain 
score of at least 4 on an 11-point numerical rating scale 
(0 = no pain; 10 = worst possible pain) during the 7-day 
baseline period. In addition, patients were required to have 
a score of  40 mm on the 100 mm VAS of the SF-MPQ at 
Table 1 Dosage adjustment of pregabalin based on renal clearance20
Creatinine clearance (ml/min) Total daily dose of pregabalin (mg/day) Total daily dose to be divided
 60 150 300 450 600 2–3 times daily
30–59 75 150 225 300 2–3 times daily
15–29 25–50 75 100–150 150 Once or twice daily
 15 25 25–50 50–75 75 Once daily
Supplemental dose after HDa 25–50 50–75 75–100 100–150
aSupplemental dose after hemodialysis is a single dose to be administered after each 4-hour hemodialysis session.
Abbreviation: HD, hemodialysis.Clinical Interventions in Aging 2009:4 20
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baseline and at randomization. The primary efﬁ  cacy point 
was the mean of the last 7 daily pain scores on the 11-point 
pain scale. Endpoint mean pain scores were signiﬁ  cantly 
reduced for both PGB 150 mg/day and PGB 300 mg/day 
groups compared to placebo. Signiﬁ  cant improvement in 
pain was noted as early as week 1 and maintained throughout 
the study. There appeared to be some additional pain relief 
from the 300 mg/day dose versus the 150 mg/day dose per 
the endpoint mean pain scores reported by the patients in 
each PGB group. Those receiving 300 mg/day of PGB 
reported a mean pain score of 4.76 as compared to a 5.14 
mean pain score in those receiving 150 mg/day; patients 
on placebo reported a mean pain score of 6.33 (p = 0.0001 
and 0.0002 for 300 mg/day and 150 mg/day versus placebo, 
respectively). A signiﬁ  cantly larger proportion of patients 
in both treatment groups obtained a  50% reduction in 
mean pain score from baseline to study end point (26% on 
150 mg/day [p = 0.006] and 28% on 300 mg/day [p = 0.003] 
versus 10% on placebo). As with the previous trial, daily 
sleep interference scores were recorded by study subjects in 
diaries using an 11-point numerical rating scale. Both doses 
of PGB signiﬁ  cantly reduced weekly mean sleep interfer-
ence scores versus placebo (3.13 for those on 150 mg/day 
[p = 0.0003], 2.81 for those on 300 mg/day [p = 0.0001] and 
4.24 for those on placebo).7
A 13-week trial in 370 patients with PHN of  3 months’ 
duration following the healing of HZ lesions was conducted 
to evaluate the efﬁ  cacy of twice daily PGB therapy.18 Stable 
medication regimens (deﬁ  ned as medications taken   30 days 
prior to study entry) of non-opioid analgesics (eg, paracetamol, 
noramidopyrine), opioids, anti-inﬂ  ammatory medications, 
and antidepressants were allowed during the trial. Prohibited 
medications included long-acting benzodiazepines, skeletal 
muscle relaxants, steroids, and anticonvulsants, among others; 
these had to be discontinued at least 7 days prior to study entry. 
Patients with a CrCl   30 mL/min were excluded from the 
trial. Patients were randomized to 1 of 4 treatment groups: 
placebo (n = 93), 150 mg/day (n = 87), 300 mg/day (n = 98), 
and 600 mg/day (n = 90). Doses were divided twice daily. 
Because a 50% reduction in CrCl is expected to result in a 
doubling of PGB exposure, patients in the 600 mg/day group 
were stratiﬁ  ed based on CrCl: patients with CrCl   60 mL/min 
received 600 mg/day, and those patients with CrCl   30 
and  60 mL/min received 300 mg/day, a dosage believed to 
provide equivalent exposure to 600 mg/day in patients with 
CrCl   60 mL/min, based on pharmacokinetic studies.18,26 
Mean age of the patients was 70.7 years, with 82% of patients 
over 65 years of age, and the mean duration of PHN was 
40.7 months. Patients were required to have an average daily 
pain score of at least 4 on an 11-point numerical rating scale 
(0 = no pain; 10 = worst possible pain) on at least 4 days during 
the 7-day baseline period. Additionally, patients were required 
to have a score of  40 mm on a 100 mm VAS at baseline and 
at randomization. Primary outcome measure was the endpoint 
mean pain score from the last 7 days of the patients’ daily pain 
diaries. As with the previous two trials discussed, this study 
assessed related sleep interference due to pain as a secondary 
outcome. Daily sleep interference scores were again recorded 
by study subjects in diaries using an 11-point numerical 
rating scale. At endpoint, PGB demonstrated significant 
dose-dependent improvement in mean pain scores and signiﬁ  -
cant improvement in mean sleep interference versus placebo. 
Mean pain scores decreased in a dose-dependent fashion as 
follows: PGB 150 mg/day was 5.26, PGB 300 mg/day 5.07, 
PGB 600 mg/day 4.35, and these were all signiﬁ  cantly lower 
versus the placebo mean pain score of 6.14 (p = 0.0077, 0.0008, 
and 0.0001, for PGB 150, 300, and 600 mg/day, respectively). 
Mean sleep interference scores showed a similar dose-
dependent pattern: PGB 150 mg/day 3.07, PGB 300 mg/day 
2.84, and PGB 600 mg/day 2.17, and these were all signiﬁ  cantly 
lower than the placebo score of 4.10 (p = 0.0007, 0.0001, and 
0.0001, for PGB 150, 300, and 600 mg/day, respectively). 
These improvements in pain and sleep were seen as early as 
Week 1 of treatment. Additionally, signiﬁ  cantly more patients 
in the PGB-treated groups demonstrated a  50% reduction 
in pain from baseline than those on placebo (26.4%, 26.5%, 
37.5%, and 7.5% in the PGB 150 mg/day, 300 mg/day, 
300/600 mg/day, and placebo groups, respectively; p = 0.001 
for each PGB group versus placebo). The number needed to 
treat (NNT) based on those with  50% reduction in pain from 
baseline for all PGB dosages combined was 4.4.18
A 12-week trial examined the efﬁ  cacy and tolerability 
of ﬂ  exible- and ﬁ  xed-dose regimens of PGB versus placebo 
in patients with PHN and painful DPN.25 PHN patients had 
pain present for  3 months after the healing of the HZ 
rash. Unlike the previously discussed trials, patients who 
had previously taken gabapentin were permitted in the trial, 
regardless of dose or duration of exposure. Use of SSRIs, 
aspirin, short-acting benzodiazepines (for insomnia), and 
paracetamol was permitted during the trial. Medications 
that were prohibited include drugs commonly used to treat 
neuropathic pain (eg, skeletal muscle relaxants, capsaicin 
cream, opioids, benzodiazepines), anticonvulsants, non-SSRI 
antidepressants, and drugs that may cause retinotoxicity (eg, 
hydroxychloroquine, thioridazine). Prohibited drugs had to 
be discontinued at least 7 days prior to the baseline visit. Clinical Interventions in Aging 2009:4 21
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Patients with CrCl   60 mL/min and those that had abused 
alcohol or illicit drugs within the past 2 years were excluded. 
Patients were randomized to placebo (n = 65), ﬂ  exible-
dose PGB (150–600 mg/day; n = 141), or ﬁ  xed-dose PGB 
(600 mg/day; n = 132). Patients randomized to the ﬂ  exible-
dose group received weekly escalating doses (150, 300, 
450, and 600 mg/day) of PGB based on response and toler-
ability. These patients were permitted a single downward 
dose titration during the ﬁ  rst 4 weeks; if this occurred, the 
patient would remain on that dosage for the study duration. 
The ﬂ  exible-dosing schedule was thought to more closely 
mimic actual clinical practice. Mean age of the patients 
was between 61 and 62 years of age, slightly younger than 
the other 3 trials. The mean duration of PHN was between 
35 and 39 months. As was the case with the previous 3 trials, 
patients were required to have a score of  40 mm on a 
100 mm VAS at baseline and at randomization. Primary 
outcome measure was the endpoint mean pain score from 
the last 7 days of the patients’ daily pain diaries according 
to the 11-point numerical pain scale discussed previously. 
This study assessed related sleep interference due to pain as 
a secondary outcome using a sleep interference diary similar 
to the other trials discussed. Flexible-dose PGB signiﬁ  cantly 
reduced mean endpoint pain scores versus placebo by Week 2 
(p = 0.021) and throughout the study (p   0.013); ﬁ  xed dose 
PGB signiﬁ  cantly reduced mean endpoint pain scores versus 
placebo by the end of Week 1 (p = 0.007) and subsequently 
throughout the rest of the trial (p   0.001). The magnitude 
in reduction of pain symptoms was similar in patients with 
either PHN or DPN. Moreover, signiﬁ  cantly more patients 
in the PGB-treated groups demonstrated a  50% reduc-
tion in pain from baseline than those on placebo (48.2% 
in the ﬂ  exible-dose PGB group, 52.3% in the ﬁ  xed-dose 
PGB group, and 24.2% in the placebo group; p   0.001 
for each PGB group versus placebo). The NNT based on 
those with  50% reduction in pain from baseline for all 
PGB-treated patients combined was 3.8. Sleep interference 
scores improved signiﬁ  cantly at endpoint over placebo for 
patients in each PGB treatment group (p   0.001 for each 
group versus placebo; exact values not given).25
Adverse effects/tolerability
The most common adverse effects with PGB treatment noted 
in PHN trials were dizziness, somnolence, and peripheral 
edema.7,14,18,25 Other notable side effects commonly reported 
with PGB use include dry mouth, blurred vision, weight gain, 
ataxia, headache, “thinking abnormal,” and nausea. Dizziness 
and somnolence were the most common adverse effects 
leading to study withdrawal.20 Dizziness and somnolence 
occurred more frequently at higher doses and began shortly 
after starting PGB.20,21 Symptoms including insomnia, nausea, 
headache, and diarrhea were reported by some patients 
following abrupt withdrawal of PGB. Therefore, PGB should 
be tapered gradually over a minimum of 1 week rather than 
discontinued abruptly. Weight gain noted in clinical trials 
of PGB was not limited to patients with peripheral edema. 
Even though weight gain was related to dose and duration 
of exposure to PGB, it did not appear to be associated with 
gender, age, or baseline BMI. A higher incidence of weight 
gain and peripheral edema were noted in patients taking 
both PGB and a thiazolidinedione, compared with patients 
taking either agent alone. Hence, care should be taken when 
co-administering PGB and one of these agents.20,21 The package 
insert cautions about the use of PGB in heart failure patients 
with NYHA Class III or IV cardiac status,20 and there have 
been reports of heart failure decompensation in patients using 
PGB for neuropathic pain.27
Place in therapy
As discussed previously, PGB and gabapentin share 
several advantages such as a lack of pharmacokinetic drug 
interactions and similar mechanism of action and efﬁ  cacy. 
It is unclear if PGB has any clinical advantage over 
gabapentin, though, as there have been no direct comparisons 
done in clinical trials between the two drugs.24 Unlike 
gabapentin, PGB exhibits linear pharmacokinetics following 
oral administration with low intersubject variability, which 
results in a more predictable dose-response relationship, since 
plasma concentrations increase linearly with increasing dose. 
Additionally, because of the pharmacokinetic advantages 
PGB has over gabapentin, patients can be initiated and 
titrated up to a target dose more rapidly. A dose-response 
relationship was demonstrated in two of the PGB trials 
discussed.7,18 Based on clinical trial data presented here and 
recommendations in PGB product labeling, patients may see 
more improvements at higher doses and should be titrated 
up to 600 mg/day if they do not experience adequate relief 
at lower doses and can tolerate the higher PGB doses.7,18,20 
Gabapentin has a cost advantage over PGB since gabapentin 
has a lower cost generic available, but the monthly cost of 
PGB is similar to generic gabapentin at the highest target 
doses of gabapentin.24,28 The long-term economic impact of 
PGB in treating PHN is unclear.24
A recently-updated meta-analysis on treatments for all 
types of neuropathic pain provides an evidence-based treatment 
algorithm for peripheral neuropathic pain. PGB/gabapentin and Clinical Interventions in Aging 2009:4 22
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TCAs/selective serotonin-norepinephrine reuptake inhibitors 
(SNRIs) were considered essentially equivalent as drugs 
of ﬁ  rst choice based on pooled NNT and number needed 
to harm (NNH) data from available RCTs.29 SNRIs show 
promise as potential therapies for other types of neuropathic 
pain, but clinical trial data to support their use for PHN are 
not yet available.29,30 PGB and gabapentin were treated as 
essentially “interchangeable” since the authors felt that the 
data were insufﬁ  cient to allow for separate analyses of PGB 
and gabapentin.19,29 If a patient has a contraindication to using 
a TCA, such as ischemic heart disease or cardiac conduction 
abnormalities, PGB/gabapentin would be preferred over a 
TCA.10,29 A subsequent cost-effectiveness analysis by Smith 
and Roberts30 largely agreed with the algorithm recommended 
by Finnerup et al29 suggesting that gabapentin/PGB and TCAs 
appeared to be reasonable ﬁ  rst choices for PHN from both a 
clinical and economic standpoint in patients without coronary 
artery disease, while gabapentin/PGB were clearly favored in 
patients with coronary artery disease or who had other contra-
indications to using TCAs.30 Smith and Roberts also examined 
PGB and gabapentin data separately, and, they noted that, if 
treated separately, gabapentin appeared to be preferred over 
PGB due to higher side effect discontinuance rates in some 
trials.30 Another cost-effective analysis comparing desipramine, 
gabapentin, and PGB for the treatment of PHN in hypothetical 
older adults 60 to 80 years of age concluded that desipramine 
was more cost-effective than the other agents.31 However, the 
study only analyzed the use of these three agents in patients 
with no known ischemic heart disease or no cardiac conduction 
abnormalities.
It is important to note that many PHN patients require 
trials of different therapies to achieve adequate pain relief; 
in fact, they often require more than 1 agent to manage their 
pain. There is no clinical trial or cost-effectiveness data 
available on PGB used in combination therapy for PHN.
Conclusion
PHN is a devastating consequence of HZ that signiﬁ  cantly 
affects patient quality of life. Despite positive ﬁ  ndings with 
several drug classes, the very heterogeneous nature of PHN 
makes successful pain management difﬁ  cult. The response 
to therapy may vary within a single patient as well as from 
patient to patient. Often, trials of more than 1 agent are 
necessary before adequate pain management is achieved. 
Regardless of which agent is tried ﬁ  rst, due to the complexity 
of PHN symptoms, it is not surprising that a single agent 
may not provide adequate pain relief. Many patients require 
a combination of therapies each ideally targeting different 
pain mechanisms. Ultimately, though, each pain management 
regimen needs to be tailored to the individual patient.
PGB appears to be an efﬁ  cacious, well-tolerated option for 
the treatment of PHN. PGB has some advantages over other 
available, recommended therapies, but cost may be an issue 
versus other established treatments. Additionally, long-term 
safety and efﬁ  cacy of PGB still need to be established.
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